Integrated Chinese and Western medicine telehealth for long-term diabetes care
Official title: Development of a New Integrated Strategy for Long-Distance and Full-Course Management of Diabetes Using Both Traditional Chinese and Western Medicine: A Combined Online and Offline Approach
Run by Shanxi Bethune Hospital · NCT07265037 · Data updated 2026-11-12
This project will test an online platform that combines Traditional Chinese Medicine and Western medicine to manage adults with type 2 diabetes remotely.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Shanxi Bethune Hospital Academic / other |
| Locations | 1 site (Taiyuan, Shanxi) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | February 28, 2026 |
| Study ends | May 31, 2026 |
| Registry record updated | December 4, 2025 |
| Trial ID | NCT07265037 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with type 2 diabetes who meet standard diagnostic glucose or HbA1c criteria, are able to use telemedicine tools, and do not have excluded severe comorbidities are ideal candidates.
✕Probably not a fit
People with active cancer, severe infections, multiple organ failure, major psychiatric disorders, rheumatic autoimmune diseases, or other conditions preventing protocol compliance are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project builds an integrated online-offline diabetes management platform that combines TCM constitution differentiation with standard Western medical examinations and laboratory tests, using the pre-developed Idata database. It will create automated follow-up pathways and personalized care plans to support long-distance, full-course management with telemedicine components. Participants meeting standard diagnostic criteria for type 2 diabetes will be enrolled at Shanxi Bethune Hospital and followed through the platform, while patients with major comorbidities are excluded. The approach aims to reduce management costs and improve efficiency by automating routine follow-up and blending traditional and modern therapies.
Why it matters
Potential benefit: If successful, the program could offer low-cost, convenient, personalized long-distance diabetes care that lowers complication risk and reduces management burden.
How similar studies have gone: Telemedicine interventions have shown benefit for glycemic control in prior studies, while deeply integrated automated platforms combining TCM and Western medicine remain relatively novel and less well tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of typical diabetes symptoms (polyuria, polydipsia, polyphagia, and unexplained weight loss) AND meeting any one of the following laboratory criteria: Fasting venous plasma glucose ≥ 7.0 mmol/L, or Random plasma glucose ≥ 11.1 mmol/L, or Glycated hemoglobin (HbA1c) ≥ 6.5%. * OR, meeting the following oral glucose tolerance test criteria:Fasting plasma glucose ≥ 7.0 mmol/L AND 2-hour plasma glucose ≥ 11.1 mmol/L after a 75g glucose load. Exclusion Criteria: * Comorbidities that may prevent compliance with the study protocol, including but not limited to: active malignancy, rheumatic autoimmune diseases, severe infections, multiple organ failure, or psychiatric disorders.
Where it's running
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, China Recruiting
Study contacts
- Study coordinator: Shiwei Liu, Doctor
- Email: lswspring6@aliyun.com
- Phone: +86 13191072733
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SpadCare: digital home-care program for patients with PICC lines
This program tests a smartphone app that teaches and remotely monitors adults with PICC lines who receive home infusions to help reduce catheter complications.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Outpatient Cardiac Telerehabilitation for Ischemic Heart Disease
This study tests whether an outpatient cardiac telerehabilitation program can be as safe and effective as conventional rehab for people with ischemic heart disease.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
AI-assisted whole-course management for safe medicine use in advanced solid tumors
A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.